首页> 外文期刊>Research on Chemical Intermediates >Synthesis, characterization, and biological evaluation of new quinazolin-4-one derivatives hybridized with pyridine or pyran moiety
【24h】

Synthesis, characterization, and biological evaluation of new quinazolin-4-one derivatives hybridized with pyridine or pyran moiety

机译:与吡啶或吡喃部分杂交的新喹唑啉-4-酮衍生物的合成,表征和生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

A new series of 2-(furan-2-yl)-4-oxoquinazolin-3-phenyl derivatives hybridized with pyridine 3a-d, 4a-d or pyran moiety 5a-d were synthesized; their structures were confirmed by spectral and elemental analysis. Cytotoxicity was evaluated on three cancer cell lines (HEPG2, HCT116 and MCF7) using the sulphorodamine-B assay method and doxorubicin as a reference drug. Compound 5d showed a closely similar activity to doxorubicin on MCF7; their IC50 values are 4.6 and 4.4 nmol/mL, respectively. In addition, compounds 4b and 4c exhibited a closely similar activity to doxorubicin on HEPG2 cancer cells; their IC50 values expressed in nmol/mL are 6.6, 6.7, and 5.7, respectively. Moreover, compound 4b (IC50 = 1.2 nmol/mL) was four times more potent than doxorubicin (IC50 = 4.8 nmol/mL) on HCT116, and compound 5d (IC50 = 0.2 nmol/mL) revealed potency equal to 24 times the potency of doxorubicin on the same cancer cell line. The most active compounds were screened against EGFR TK, and results showed that compound 5d was the most potent inhibitor; its percentage of inhibition was 95.6. Furthermore, compound 5d was docked into the EGFR binding site to explore its possible interactions with EGFR TK.
机译:合成了与吡啶3a-d,4a-d或吡喃部分5a-d杂交的一系列新的2-(呋喃-2-基)-4-氧代喹唑啉-3-苯基衍生物。通过光谱和元素分析证实了它们的结构。使用磺基罗丹明-B测定法和阿霉素作为参考药物,评估了三种癌细胞系(HEPG2,HCT116和MCF7)的细胞毒性。化合物5d在MCF7上显示出与阿霉素非常相似的活性。其IC50值分别为4.6和4.4 nmol / mL。此外,化合物4b和4c在HEPG2癌细胞上表现出与阿霉素极为相似的活性;其以nmol / mL表示的IC50值分别为6.6、6.7和5.7。此外,在HCT116上,化合物4b(IC50 = 1.2 nmol / mL)的效力是阿霉素(IC50 = 4.8 nmol / mL)的效力的四倍,化合物5d(IC50 = 0.2 nmol / mL)的效力等于甲壳素的24倍阿霉素在同一癌细胞系上。筛选出针对EGFR TK活性最高的化合物,结果表明化合物5d是最有效的抑制剂。其抑制百分比为95.6。此外,化合物5d停靠在EGFR结合位点,以探讨其与EGFR TK的可能相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号